Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Mantle-Cell 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Dexamethasone 338Bortezomib 188Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × WW Domain-Containing Oxidoreductase × Clear all
NCT00511238 2017-08-31

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Amgen

Phase 2 Completed
312 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT00530816 2017-05-02

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Amgen

Phase 2 Completed
164 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡